Deep Track Capital Increases Stake to 11.7% in LB Pharmaceuticals via Private Placement

summarizeSummary

Deep Track Capital, a significant institutional investor, has increased its beneficial ownership in LB Pharmaceuticals to 11.7% by participating in a recent private placement, acquiring pre-funded warrants valued at approximately $10 million.

check_boxKey Events

• Increased Beneficial Ownership

  Deep Track Capital's aggregate beneficial ownership in LB Pharmaceuticals Inc. has increased to 11.7% of outstanding common stock, up from a previously reported stake.

• Private Placement Participation

  Deep Track Capital entities acquired 472,369 pre-funded warrants in a private placement that closed on February 6, 2026, representing an investment of approximately $10 million. This follows the company's 8-K announcement on February 5, 2026, regarding the $100 million private placement.

• Warrant Exercise Limitation

  The acquired pre-funded warrants include a 9.99% ownership limitation, preventing immediate exercise if it would cause the holder's beneficial ownership to exceed this threshold.

• Registration Rights Agreement

  In connection with the private placement, the company entered into a Registration Rights Agreement, obligating it to register the shares underlying the warrants for resale within 60 days.

auto_awesomeAnalysis

This Schedule 13D/A provides updated details on Deep Track Capital's significant stake in LB Pharmaceuticals following their participation in the recently announced private placement. Their investment of approximately $10 million in pre-funded warrants, which was previously disclosed in a Form 4, demonstrates continued confidence from a major institutional investor. While the private placement itself is dilutive and was priced at a discount to the current market, securing capital from a key investor is crucial for the company's operations, especially given the prior 8-K announcement of a $100 million raise to fund a pivotal program. The 9.99% ownership limitation on the warrants is a notable detail, managing the immediate potential for further dilution from these specific securities.